{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
An observational survey study to analyze the management of Interstitial lung diseases
  1. Approximately, how many patients of Interstitial lung diseases (ILD) do you see in your practice every month? *

  2. Approximately, how many patients are newly diagnosed with Interstitial lung diseases (ILD) in your practice every month? *

  3. Approximately, how many patients are newly diagnosed with idiopathic pulmonary fibrosis (IPF) in your practice every month? *

  4. What is the approximate break up of patients in percentage based on type of ILD, as observed in your practice? *
    5. Percentage
    Idiopathic pulmonary fibrosis (IPF)
    Sarcoidosis
    Connective tissue disease (CTD)- related ILDs
    Hypersensitivity pneumonitis
    Other ILDs
    Total 100%
  5. Which are the common presenting symptoms among patients with interstitial lung disease, as observed in your practice? (Tick all applicable) *

  6. What is the approximate percentage of patients where the below diagnostic tests are performed for diagnosis of patients with ILD, as per your practice? *
    7. Percentage
    Sputum AFB
    Spirometry
    CTD serology
    HRCT -high-resolution computed tomography
    CXR = chest radiograph
  7. Which is the most common age group when patients are diagnosed with ILD according to the type of ILD, as observed in your practice? (Tick all which are applicable) *
    8. ≤ 18 yrs >18-30 yrs 31 to 45 yrs 46- 60 yrs >60 yrs
    Idiopathic pulmonary fibrosis (IPF)

    Sarcoidosis

    Connective tissue disease (CTD)- related ILDs

    Hypersensitivity pneumonitis

    Other ILDs

  8. What is the approximate number of patients in of ILD where Transbronchial lung biopsy is done, as observed in your practice? (Tick the applicable) *

  9. Which are the common comorbidities seen in IPF patients? (Tick all relevant options) *

  10. Other diagnostic requirements apart from HRCT? *

  11. Approximately, how many patients newly diagnosed with Interstitial lung diseases (ILD) have a history of smoking, as observed in your practice? *

  12. Approximately, how many patients newly diagnosed with Interstitial lung diseases (ILD) have a history of tuberculosis, as observed in your practice? *

  13. Which is antifibrotic of choice in patients with IPF? *

  14. Which is antifibrotic of choice in patients newly diagnosed with IPF? *

  15. Which are the key attributes for selecting the preferred antifibrotic in your patients with ILD? (Tick all the relevant options)*

  16. Do you agree that dosing and frequency is an advantage of Nintedanib over Pirfenidone? *

  17. Which is the preferred antifibrotic in patients with IPF having obesity? *

  18. How frequently do you need to switch from one antifibrotic to another in your patients with IPF? *

  19. When do you switch a patient from Pirfenidone to Nintedanib in your patients with IPF? *

  20. Which is antifibrotic of choice in treatment- naive patients of IPF? *

  21. Which feature on HRCT is most important to assess response to antifibrotic treatment? *

  22. What percentage of IPF patients present with definite Usual interstitial pneumonia on HRCT/Histopathology? *

  23. For how long antifibrotics are given in your patients with IPF? *

  24. What is the frequency of follow up of IPF patients? *

  25. How is the response to anti fibrotic treatment is assessed in patients with IPF? *

  26. How is the response to anti fibrotic treatment is assessed in patients with IPF? *

  27. How many IPF patients receive combination of anti-fibrotic agents, as observed in your practice? *

  28. Kindly share the approximate break up of usage of Nintedanib as per patient profile in patients with IPF, in your clinical practice? *
    29. Condition Percentage
    Newly diagnosed
    Treatment experienced
    Total percentage 100%
  29. Kindly share the approximate break up of usage of Pirfenidone as per patient profile in patients with IPF, in your clinical practice? *
    30. Condition Percentage
    Newly diagnosed
    Treatment experienced
    Total percentage 100%
  30. How would you rate the Nintedanib for below parameters for IPF in terms of improvement from baseline, as observed in your practice? *
    31. Strongly recommended Recommended Neutral
    6-min walking distance

    DLco: diffusion of carbon monoxide;

    FVC: Forced Vital Capacity

    SpO2 : Oxygen saturation by pulse oximetry

  31. How would you rate the Pirfenidone for below paramers for IPF in terms of improvement from baseline, as observed in your practice? *
    32. Strongly recommended Recommended Neutral
    6-min walking distance

    DLco: diffusion of carbon monoxide;

    FVC: Forced Vital Capacity

    SpO2 : Oxygen saturation by pulse oximetry